Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Loco-Regional Arterial Chemotherapies Alone or in Combination with Sistemic Treatments...
share announcement

Loco-Regional Arterial Chemotherapies Alone or in Combination with Sistemic Treatments for Primary and Secondary Hepato-Pancreatic Tumors

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 12957

Special Issue Editor

Prof. Dr. Girolamo Ranieri

E-Mail
Guest Editor
Department of Interventional and Integrated Medical Oncology, National Cancer Research Centre, IRCCS Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco 65, 70124 Bari, Italy
Interests: primary and metastatic liver tumors; pancreatic tumors; colorectal cancers; breast cancers; intra-arterial chemotherapy; chemoembolization; translational oncology angiogenesis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Many types of tumor have a typical metastatic site. For example, colorectal and pancreatic cancers metastatize almost exclusively to the liver. Massive hepatic metastatic involvement is responsible for liver functional failure and patient death despite other organs usually having a lower burden of disease. Few cancer centers use the treatment strategy to combine classical systemic chemotherapy with locoregional chemotherapy on the most involved metastatic site. This approach could control the systemic spread of the tumor and the local disease in the main metastatic site. Moreover, locoregional and systemic chemotherapy-based schedules combine the advantages of an increased pharmacological effect in the target metastatic site with a reduction of the systemic side effects. In literature, there are interesting data about the clinical results derived from hepatic artery infusion (HAI) for the management of liver metastases and hepato-pancreatic artery infusion (H-PAI) for the treatment of primary pancreatic cancer with liver metastases. For this Special Issue, our aim is to increase awareness of the benefits of a combined anticancer treatments approach by discussing the various clinical results that can be obtained.

Prof. Dr. Girolamo Ranieri
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Hepatic arterial infusion (HAI)
  • Transarterial chemoembolization (TACE)
  • Arteriography
  • Primary and metastatic liver tumors
  • Primary pancreatic tumors
  • Systemic chemotherapy
  • Biological agents
  • Tyrosine kinase inhibitors
  • Oxaliplatin
  • 5-Fluorouracil
  • Irinotecan
  • Gemcitabine
  • Adriblastin

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Editorial

Jump to: Research, Review

3 pages, 178 KiB  
Editorial
Loco-Regional and Systemic Chemotherapies for Hepato-Pancreatic Tumors: Integrated Treatments
by Girolamo Ranieri and Carmelo Laface
Cancers 2020, 12(10), 2737; https://doi.org/10.3390/cancers12102737 - 24 Sep 2020
Cited by 11 | Viewed by 1520
Abstract
This Special Issue of Cancers, titled “Loco-Regional Arterial Chemotherapies Alone or in Combination with Systemic Treatments for Primary and Secondary Hepato-Pancreatic Tumors”, focuses on new possible strategies to treat only liver disease (or mainly liver disease) through the combination of loco-regional and [...] Read more.
This Special Issue of Cancers, titled “Loco-Regional Arterial Chemotherapies Alone or in Combination with Systemic Treatments for Primary and Secondary Hepato-Pancreatic Tumors”, focuses on new possible strategies to treat only liver disease (or mainly liver disease) through the combination of loco-regional and systemic chemotherapies [...] Full article
(This article belongs to the Special Issue Loco-Regional Arterial Chemotherapies Alone or in Combination with Sistemic Treatments for Primary and Secondary Hepato-Pancreatic Tumors)

Research

Jump to: Editorial, Review

16 pages, 366 KiB  
Article
Prognostic Role of Neutrophil-to-Lymphocyte Ratio (NLR), Lymphocyte-to-Monocyte Ratio (LMR), Platelet-to-Lymphocyte Ratio (PLR) and Lymphocyte-to-C Reactive Protein Ratio (LCR) in Patients with Hepatocellular Carcinoma (HCC) undergoing Chemoembolizations (TACE) of the Liver: The Unexplored Corner Linking Tumor Microenvironment, Biomarkers and Interventional Radiology
by Roberto Minici, Maria Anna Siciliano, Michele Ammendola, Rita Carlotta Santoro, Vito Barbieri, Girolamo Ranieri and Domenico Laganà
Cancers 2023, 15(1), 257; https://doi.org/10.3390/cancers15010257 - 30 Dec 2022
Cited by 11 | Viewed by 2922
Abstract
TACE plays a pivotal role in hepatocellular carcinoma, from disease control to downstaging and bridging to liver transplant. Response to TACE is a surrogate marker of tumor aggressive biology, with manifold practical implications such as survival, the need for more aggressive treatments in [...] Read more.
TACE plays a pivotal role in hepatocellular carcinoma, from disease control to downstaging and bridging to liver transplant. Response to TACE is a surrogate marker of tumor aggressive biology, with manifold practical implications such as survival, the need for more aggressive treatments in the intermediate stage, the selection of patients on the transplant waiting list, the dropout rate from the transplant list and the post-transplant recurrence rate. Inflammation-based scores are biomarkers of the relationship between the tumor stromal microenvironment and the immune response. Investigating the connection among the tumor stromal microenvironment, biomarkers, and the response to TACE is crucial to recognize TACE refractoriness/failure, thus providing patients with tailored therapeutics. This review aims to provide a comprehensive overview of the prognostic roles of the neutrophil-to-lymphocyte ratio (NLR), the lymphocyte-to-monocyte ratio (LMR), the platelet-to-lymphocyte ratio (PLR), and the lymphocyte-to-C reactive protein ratio (LCR) in patients with HCC undergoing chemoembolization of the liver. Inflammation-based scores may be convenient, easily obtained, low-cost, and reliable biomarkers with prognostic significance for HCC undergoing TACE. Baseline cut-off values differ between various studies, thus increasing confusion about using of inflammation-based scores in clinical practice. Further investigations should be conducted to establish the optimal cut-off values for inflammation-based scores, consolidating their use in clinical practice. Full article
(This article belongs to the Special Issue Loco-Regional Arterial Chemotherapies Alone or in Combination with Sistemic Treatments for Primary and Secondary Hepato-Pancreatic Tumors)

Review

Jump to: Editorial, Research

14 pages, 1481 KiB  
Review
Intra-Arterial Infusion Chemotherapy in Advanced Pancreatic Cancer: A Comprehensive Review
by Carmelo Laface, Mariarita Laforgia, Pasquale Molinari, Caterina Foti, Francesca Ambrogio, Cosmo Damiano Gadaleta and Girolamo Ranieri
Cancers 2022, 14(2), 450; https://doi.org/10.3390/cancers14020450 - 17 Jan 2022
Cited by 9 | Viewed by 3672
Abstract
Advanced pancreatic cancer (PC) has a very poor prognosis due to its chemoresistant nature. Nowadays, only a few therapeutic options are available for PC, and the most effective ones are characterized by low response rates (RRs), short progression-free survival and overall survival, and [...] Read more.
Advanced pancreatic cancer (PC) has a very poor prognosis due to its chemoresistant nature. Nowadays, only a few therapeutic options are available for PC, and the most effective ones are characterized by low response rates (RRs), short progression-free survival and overall survival, and severe toxicity. To improve clinical results, small series studies have evaluated loco-regional chemotherapy as a treatment option for PC, demonstrating its dose-dependent sensitivity towards the tumor. In fact, pancreatic arterial infusion (PAI) chemotherapy allows higher local concentrations of chemotherapeutic agents, sparing healthy tissues with a lower rate of adverse events compared to systemic chemotherapy. This therapeutic approach has already been evaluated in different types of tumors, especially in primary and metastatic liver cancers, with favourable results. With regard to advanced PC, a few clinical studies have investigated the safety and efficacy of PAI with promising results, especially in terms of RRs compared to systemic chemotherapy. However, clear evidence about its efficacy has not been established yet nor have the underlying mechanisms leading to its success. In this review, we aim to summarize the literature data on the clinical approaches to pancreatic arterial drug administration in terms of techniques, drug pharmacokinetics, and clinical outcomes for advanced PC. Full article
(This article belongs to the Special Issue Loco-Regional Arterial Chemotherapies Alone or in Combination with Sistemic Treatments for Primary and Secondary Hepato-Pancreatic Tumors)
►▼ Show Figures

Figure 1

23 pages, 2216 KiB  
Review
Hepatic Arterial Infusion of Chemotherapy for Advanced Hepatobiliary Cancers: State of the Art
by Carmelo Laface, Mariarita Laforgia, Pasquale Molinari, Ippazio Ugenti, Cosmo Damiano Gadaleta, Camillo Porta and Girolamo Ranieri
Cancers 2021, 13(12), 3091; https://doi.org/10.3390/cancers13123091 - 21 Jun 2021
Cited by 15 | Viewed by 3871
Abstract
Liver functional failure is one of the leading causes of cancer-related death. Primary liver tumors grow up mainly in the liver, and thus happens for liver metastases deriving from other organs having a lower burden of disease at the primary site. Systemic chemotherapy [...] Read more.
Liver functional failure is one of the leading causes of cancer-related death. Primary liver tumors grow up mainly in the liver, and thus happens for liver metastases deriving from other organs having a lower burden of disease at the primary site. Systemic chemotherapy usually offers a modest benefit in terms of disease control rate, progression-free survival, and overall survival at the cost of a significant percentage of adverse events. Liver malignancies are mostly perfused by the hepatic artery while the normal liver parenchyma by the portal vein network. On these bases, the therapeutic strategy consisting of hepatic arterial infusion (HAI) of chemotherapy takes place. In literature, HAI chemotherapy was applied for the treatment of advanced hepatobiliary cancers with encouraging results. Different chemotherapeutic agents were used such as Oxaliplatin, Cisplatin, Gemcitabine, Floxuridine, 5-Fluorouracil, Epirubicin, individually or in combination. However, the efficacy of this treatment strategy remains controversial. Therefore, this review aims to summarize the current knowledge on this approach from different points of view, such as techniques, drugs pharmacology and pharmacokinetics, and clinical outcomes for advanced hepatobiliary cancers. Full article
(This article belongs to the Special Issue Loco-Regional Arterial Chemotherapies Alone or in Combination with Sistemic Treatments for Primary and Secondary Hepato-Pancreatic Tumors)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop